Grail's Galleri blood test fails to meet standards in large cancer screening study, shares drop 50%

Despite the lack of statistical significance, Grail said the observation of improving trends suggested the potential for better results over time, so the company extended follow-up by one year. More detailed trial results will be presented at the American Society of Clinical Oncology annual meeting.

The post Grail’s Galleri blood test falls 50% after failing standards in large cancer screening study appeared first on MedCity News.